SUPPLEMENTARY TABLE 1. Characteristics of emergency department and urgent care encounters and hospitalizations among immunocompetent adults aged ≥18 years with COVID-19-like illness, by SARS-CoV-2 test result status and CDC vaccine effectiveness network, including control-patients with positive or indeterminant influenza test results — VISION and IVY Networks, September 2023–January 2024

All ED/UC encounters  143,146  17,229  125,917  — — — — — — — — — — — — — — — — — —	,	No. (Col. %)							
Characteristic   Total   Case-patients   Control-patients   Total   Case-patients   Control-patients   Con									
All ED/UC encounters  143,146  17,229  125,917  ———————————————————————————————————			COVID-19	COVID-19		COVID-19	COVID-19		
Vaccination status   No updated dose, 2* No updated dose, 2* I day, 2 earlier   15,935 (11)   1,297 (8)   111,279 (88)   — — — — — — — — — — — — — — — — — —	Characteristic	Total	case-patients	control-patients	Total	case-patients	control-patients		
No updated dose*    127,211 (89)   15,932 (92)   111,279 (88)   -   -   -	All ED/UC encounters	143,146	17,229	125,917	_	_	_		
Updated dose, ≥7 days earlier  Updated dose, ≥7 days earlier  15,935 (11)  1,297 (8)  14,638 (12)  — — — — — — — — — — — — — — — — — —	Vaccination status								
Updated dose, 7–59 days earlier  Updated dose, 60–119 days earlier  5,097 (4)  472 (3)  4,625 (4)  — — —  Median age, yrs (IQR)  51 (33, 70)  54 (35, 72)  50 (33, 69)  — — —  Age group, yrs  18–64  96,924 (68)  10,959 (64)  85,965 (68)  — — —  Female sex  86,974 (61)  10,292 (60)  76,682 (61)  — —  Race and ethnicity  Black or African American, NH  14,717 (10)  1,425 (8)  13,292 (11)  — — —  White, NH  89,710 (63)  11,594 (67)  78,116 (62)  — — —  Hispanic or Latino, any race  21,674 (15)  2,316 (13)  19,358 (15)  — — —  HHS region¹  1  0 (—)  0 (—)  0 (—)  0 (—)  3  0 (—)  0 (—)  0 (—)  4  0 (—)  0 (—)  0 (—)  0 (—)  4  0 (—)  0 (—)  0 (—)  0 (—)  3  0 (—)  0 (—)  0 (—)  0 (—)  4 (4)  0 (—)  0 (—)  0 (—)  0 (—)  0 (—)  77  0 (—)  0	No updated dose*	127,211 (89)	15,932 (92)	111,279 (88)	_	_	_		
Updated dose, 60–119 days earlier   5,097 (4)   472 (3)   4,625 (4)	Updated dose, ≥7 days earlier	15,935 (11)	1,297 (8)	14,638 (12)	_	_	_		
Median age, yrs (IQR)         51 (33, 70)         54 (35, 72)         50 (33, 69)         —         —         —           Age group, yrs           18–64         96,924 (68)         10,959 (64)         85,965 (68)         —	Updated dose, 7–59 days earlier	10,838 (8)	825 (5)	10,013 (8)	_	_	_		
Age group, yrs  18-64   96,924 (68)   10,959 (64)   85,965 (68)   -   -   -    265   46,222 (32)   6,270 (36)   39,952 (32)   -   -    Female sex   86,974 (61)   10,292 (60)   76,682 (61)   -   -    Race and ethnicity  Black or African American, NH   14,717 (10)   1,425 (8)   13,292 (11)   -     -    White, NH   89,710 (63)   11,594 (67)   78,116 (62)   -     -    Hispanic or Latino, any race   21,674 (15)   2,316 (13)   19,358 (15)   -     -    Other, NH   14,370 (10)   1,590 (9)   12,780 (10)   -     -    Unknown   2,675 (2)   304 (2)   2,371 (2)   -     -    HISF region*  1	Updated dose, 60–119 days earlier	5,097 (4)	472 (3)	4,625 (4)	_	_	_		
18-64 96,924 (68) 10,959 (64) 85,965 (68) — — — — — — — — — — — — — — — — — — —	Median age, yrs (IQR)	51 (33, 70)	54 (35, 72)	50 (33, 69)	_	_	_		
Acceptable   Acc	Age group, yrs								
Female sex	18–64	96,924 (68)	10,959 (64)	85,965 (68)	_	_	_		
Race and ethnicity  Black or African American, NH	≥65	46,222 (32)	6,270 (36)	39,952 (32)	_	_	_		
Black or African American, NH	Female sex	86,974 (61)	10,292 (60)	76,682 (61)	_	_	_		
White, NH	Race and ethnicity								
Hispanic or Latino, any race  21,674 (15) 2,316 (13) 19,358 (15) Other, NH† 14,370 (10) 1,590 (9) 12,780 (10)	Black or African American, NH	14,717 (10)	1,425 (8)	13,292 (11)	_	_	_		
Other, NH <sup>†</sup> 14,370 (10) 1,590 (9) 12,780 (10) — — — — — — — — — — — — — — — — — — —	White, NH	89,710 (63)	11,594 (67)	78,116 (62)	_	_	_		
Unknown§ 2,675 (2) 304 (2) 2,371 (2) — — — — — — HHS region¶  1 0 (—) 0 (—) 0 (—) 0 (—) — — — — — — — — — — — — — — — — — —	Hispanic or Latino, any race	21,674 (15)	2,316 (13)	19,358 (15)	_	_	_		
HHS region <sup>¶</sup> 1	Other, NH <sup>†</sup>	14,370 (10)	1,590 (9)	12,780 (10)	_	_	_		
1 0 (-) 0 (-) 0 (-) 0 (-)	Unknown <sup>§</sup>	2,675 (2)	304 (2)	2,371 (2)	_	_	_		
2	HHS region¶								
0 (−) 0 (−) 0 (−) − − − − − − − − − − − − − − − − − −	1	0 (—)	0 (—)	0 (—)	_	_	_		
4	2	0 (—)	0 (—)	0 (—)	_	_	_		
5	3	0 (—)	0 (—)	0 (—)	_	_	_		
6 0 (−) 0 (−) 0 (−) − − − − − − − − − − − − − − − − − −	4	0 (—)	0 (—)	0 (—)	_	_	_		
7         0 (-)         0 (-)         0 (-)         -         -         -           8         43,864 (31)         7,466 (43)         36,398 (29)         -         -         -           9         41,173 (29)         2,829 (16)         38,344 (30)         -         -         -           10         9,464 (7)         1,027 (6)         8,437 (7)         -         -         -           No. of chronic medical condition categories**         -         -         -         -         -         -           1         27,399 (19)         2,542 (15)         24,857 (20)         -         -         -         -           2         6,969 (5)         814 (5)         6,155 (5)         -         -         -         -           3         2,532 (2)         230 (1)         2,302 (2)         -         -         -         -           4         738 (1)         84 (0.5)         654 (1)         -         -         -         -           4         738 (1)         19 (0.1)         176 (0.1)         -         -         -         -           4         738 (1)         84 (0.5)         654 (1)         -         -         -         - <td>5</td> <td>48,645 (34)</td> <td>5,907 (34)</td> <td>42,738 (34)</td> <td>_</td> <td>_</td> <td>_</td>	5	48,645 (34)	5,907 (34)	42,738 (34)	_	_	_		
8	6	0 (—)	0 (—)	0 (—)	_	_	_		
9	7	0 (—)	0 (—)	0 (—)	_	_	_		
10	8	43,864 (31)	7,466 (43)	36,398 (29)	_	_	_		
No. of chronic medical condition categories**  0	9	41,173 (29)	2,829 (16)	38,344 (30)	_	_	_		
0	10	9,464 (7)	1,027 (6)	8,437 (7)	_	_	_		
1 27,399 (19) 2,542 (15) 24,857 (20) — — — — — — — — — — — — — — — — — — —	No. of chronic medical condition cate	gories**							
2 6,969 (5) 814 (5) 6,155 (5) — — — — — — — — — — — — — — — — — — —	0	105,313 (74)	13,540 (79)	91,773 (73)	_	_	_		
3     2,532 (2)     230 (1)     2,302 (2)     —     —     —       4     738 (1)     84 (0.5)     654 (1)     —     —     —       25     195 (⊕0.1)     19 (0.1)     176 (0.1)     —     —     —       Month of COVID-19-associated ED/UC encounter       September 2023       9,834 (7)     1,222 (7)     8,612 (7)     —     —     —       October 2023     30,170 (21)     3,521 (20)     26,649 (21)     —     —     —	1	27,399 (19)	2,542 (15)	24,857 (20)	_	_	_		
738 (1) 84 (0.5) 654 (1) — — — — — — — — — — — — — — — — — — —	2	6,969 (5)	814 (5)	6,155 (5)	_	_	_		
195 (00.1)   19 (0.1)   176 (0.1)   -   -   -	3	2,532 (2)	230 (1)	2,302 (2)	_	_	_		
Month of COVID-19-associated ED/UC encounter           September 2023         9,834 (7)         1,222 (7)         8,612 (7)         —         —         —         —           October 2023         30,170 (21)         3,521 (20)         26,649 (21)         —         —         —	4	738 (1)	84 (0 <u>.5</u> )	654 (1)		_	_		
September 2023         9,834 (7)         1,222 (7)         8,612 (7)         —         —         —           October 2023         30,170 (21)         3,521 (20)         26,649 (21)         —         —         —	≥5	195 ( <del>0</del> 0.1)	19 (0 <u>.1</u> )	176 (0 <u>.1</u> )		_			
October 2023 30,170 (21) 3,521 (20) 26,649 (21) — — —	Month of COVID-19-associated ED/U	C encounter							
October 2023 30,170 (21) 3,521 (20) 26,649 (21) — — — —	September 2023	9,834 (7)	1,222 (7)	8,612 (7)	_	_	_		
November 2023 36,142 (25) 4,487 (26) 31,655 (25) — — — —	October 2023	30,170 (21)		26,649 (21)	_	_	_		
	November 2023	36,142 (25)	4,487 (26)	31,655 (25)	_	_	_		

December 2023	51,306 (36)	6,289 (37)	45,017 (36)	_	_	_
January 2024	15,694 (11)	1,710 (10)	13,984 (11)	_	_	_
SARS-CoV-2 JN.1 lineage	31,201 (22)	3,597 (21)	27,604 (22)	<u> </u>	_	_
predominant period <sup>††</sup>						
All hospitalizations	39,322	4,589	34,733	4,628	1,194	3,434
Vaccination status						
No updated dose*	34,476 (88)	4,194 (91)	30,282 (87)	4,124 (89)	1,100 (92)	3,024 (88)
Updated dose, ≥7 days earlier	4,846 (12)	395 (9)	4,451 (13)	504 (11)	94 (8)	410 (12)
Updated dose, 7–59 days earlier	3,459 (9)	270 (6)	3,189 (9)	314 (7)	57 (5)	257 (7)
Updated dose, 60–119 days earlier	1,387 (4)	125 (3)	1,262 (4)	190 (4)	37 (3)	153 (4)
Median age, yrs (IQR)	71 (59–81)	77 (67–84)	70 (58–81)	67 (55–77)	73 (61–82)	65 (52–76)
Age group, yrs						
18–64	13,798 (35)	976 (21)	12,822 (37)	2,063 (45)	371 (31)	1,692 (49)
≥65	25,524 (65)	3,613 (79)	21,911 (63)	2,565 (55)	823 (69)	1,742 (51)
Female sex	21,116 (54)	2,365 (52)	18,751 (54)	2,394 (52)	623 (52)	1,771 (52)
Race and ethnicity						
Black or African American, NH	4,229 (11)	346 (8)	3,883 (11)	1,061 (23)	226 (19)	835 (24)
White, NH	27,595 (70)	3,479 (76)	24,116 (69)	2,613 (56)	752 (63)	1,861 (54)
Hispanic or Latino, any race	3,759 (10)	354 (8)	3,405 (10)	619 (13)	133 (11)	486 (14)
Other, NH <sup>†</sup>	3,315 (8)	373 (8)	2,942 (8)	177 (4)	40 (3)	137 (4)
Unknown <sup>§</sup>	424 (1)	37 (1)	387 (1)	158 (3)	43 (4)	115 (3)
HHS region <sup>¶</sup>						
1	0 (—)	0 (—)	0 (—)	971 (21)	330 (28)	641 (19)
2	0 (—)	0 (—)	0 (—)	312 (7)	62 (5)	250 (7)
3	0 (—)	0 (—)	0 (—)	41 (1)	14 (1)	27 (1)
4	0 (—)	0 (—)	0 (—)	597 (13)	125 (10)	472 (14)
5	18,193 (46)	2,154 (47)	16,039 (46)	559 (12)	160 (13)	399 (12)
6	0 (—)	0 (—)	0 (—)	607 (13)	129 (11)	478 (14)
7	0 (—)	0 (—)	0 (—)	145 (3)	36 (3)	109 (3)
8	7,493 (19)	1,061 (23)	6,432 (19)	860 (19)	194 (16)	666 (19)
9	11,807 (30)	1,211 (26)	10,596 (31)	359 (8)	101 (8)	258 (8)
10	1,829 (5)	163 (4)	1,666 (5)	177 (4)	43 (4)	134 (4)
No. of chronic medical condition cate	gories**					
0	5,391 (14)	643 (14)	4,748 (14)	456 (10)	98 (8)	358 (10)
1	6,670 (17)	624 (14)	6,046 (17)	937 (20)	237 (20)	700 (20)
2	7,644 (19)	847 (18)	6,797 (20)	1,314 (28)	340 (28)	974 (28)
3	9,660 (25)	1,255 (27)	8,405 (24)	1,084 (23)	290 (24)	794 (23)
4	6,818 (17)	830 (18)	5,988 (17)	566 (12)	156 (13)	410 (12)
≥5	3,139 (8)	390 (8)	2,749 (8)	271 (6)	73 (6)	198 (6)
Month of COVID-19-associated hosp	italization					
September 2023	2,966 (8)	270 (6)	2,696 (8)	333 (7)	126 (11)	207 (6)
October 2023	9,840 (25)	1,011 (22)	8,829 (25)	1,110 (24)	352 (29)	758 (22)
November 2023	10,749 (27)	1,283 (28)	9,466 (27)	1,121 (24)	300 (25)	821 (24)
December 2023	12,926 (33)	1,674 (36)	11,252 (32)	1,146 (25)	230 (19)	916 (27)
January 2024	2,841 (7)	351 (8)	2,490 (7)	918 (20)	186 (16)	732 (21)
SARS-CoV-2 JN.1 lineage	6,264 (16)	807 (18)	5,457 (16)	1,135 (25)	231 (19)	904 (26)
predominant period <sup>††</sup>						

**Abbreviations:** ED/UC = emergency department/urgent care; HHS = U.S. Department of Health and Human Services; IVY = Investigating Respiratory Viruses in the Acutely III; NH = non-Hispanic; VISION = Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network.

- \* The "no updated dose" group included all eligible persons who did not receive an updated (2023-2024) COVID-19 vaccine dose, regardless of number of previous (i.e., original monovalent and bivalent) doses received (if any).
- <sup>†</sup> For VISION, "Other, NH" race persons reporting NH ethnicity and any of the following for race: American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, other races not listed, and multiple races. Because of small numbers, these categories were combined. For IVY, "Other race, NH" includes Asian, Native American or Alaska Native, and Native Hawaiian or other Pacific Islander; these groups were combined due to small counts.
- § For VISION, "Unknown" includes persons with missing race and ethnicity in their EHR. For IVY, "Unknown" includes patients who self-reported their race and ethnicity as "Other" and those for whom race and ethnicity were unknown.
- Regions are defined by HHS. States included in each region are available at https://www.hhs.gov/about/agencies/iea/regionaloffices/index.html. VISION Network sites included: Region 5: HealthPartners (Minnesota and Wisconsin) and Regenstrief Institute (Indiana); Region 8: Intermountain Healthcare (Utah) and University of Colorado (Colorado); Region 9: Kaiser Permanente Northern California (California); and Region 10: Kaiser Permanente Northwest (Oregon and Washington). IVY Network sites included: Region 1: Baystate Medical Center (Springfield, Massachusetts), Beth Israel Deaconess Medical Center (Boston, Massachusetts), and Yale University (New Haven, Connecticut); Region 2: Montefiore Medical Center (New York, New York); Region 3: Johns Hopkins Hospital (Baltimore, Maryland); Region 4: Emory University Medical Center (Atlanta, Georgia), University of Miami Medical Center (Miami, Florida), Vanderbilt University Medical Center (Nashville, Tennessee), and Wake Forest University Baptist Medical Center (Winston-Salem, North Carolina); Region 5: Cleveland Clinic (Cleveland, Ohio), Hennepin County Medical Center (Minneapolis, Minnesota), Henry Ford Health (Detroit, Michigan), The Ohio State University Wexner Medical Center (Columbus, Ohio), and University of Michigan Hospital (Ann Arbor, Michigan); Region 6: Baylor Scott & White Medical Center (Temple, Texas) and Baylor University Medical Center (Dallas, Texas); Region 7: Barnes-Jewish Hospital (St. Louis, Missouri) and University of Iowa Hospitals (Iowa City, Iowa); Region 8: Intermountain Medical Center (Murray, Utah), UCHealth University of Colorado Hospital (Aurora, Colorado), and University of Utah (Salt Lake City, Utah); Region 9: Stanford University Medical Center (Stanford, California), Ronald Reagan UCLA Medical Center (Los Angeles, California), and University of Arizona Medical Center (Tucson, Arizona); and Region 10: Oregon Health & Science University Hospital (Portland, Oregon) and University of Washington (Seattle, Washington).
- \*\* VISION underlying condition categories included: pulmonary, cardiovascular, cerebrovascular, neurologic or musculoskeletal, hematologic, endocrine, renal, gastrointestinal. IVY underlying condition categories included: pulmonary, cardiovascular, neurologic, hematologic, endocrine, renal, gastrointestinal, and autoimmune.
- <sup>††</sup> The JN.1 predominant period was considered to have started December 24, 2023.